Cilostazol

This classification denotes a phosphodiesterase inhibitor and antiplatelet agent with the molecular formula C20H27N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N7Z035406B, chemically known as 3,4-dihydro-6-(4-(1-cyclohexyl-1h-tetrazol-5-yl)butoxy)-2(1h)-quinolinone but generally known as cilostazol, which bears US NIH Compound Identifier 2754. European Medicines Agency schedules Cilostazol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06273MIG. The term CILOSTAZOL is an International Non-Proprietary Name. World Health Organization schedules cilostazol in its Anatomical Therapeutic Chemical (ATC) Classification. CILOSTAZOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cilostazol under HS 29337900 and SITC 51561. As of Q4 2014, CILOSTAZOL remains the US FDA Preferred Term for this commodity. Cilostazol bears US NLM identifiers UMLS ID C0055729 and NCI Concept Code C1051. SMILES: O(CCCCC1N(NNN1)C1CCCCC1)C1CC2CCC(=O)NC2CC1.